The efficacy of rituximab in consolidation treatment after chemotherapy CHOP in patients with follicular lymphoma
2005
Abstract
The aim was to evaluate the efficacy of monoclonal antibody anti CD20 ? rituximab ? as a consolidation therapy after induction treatment of CHOP in patients with newly diagnosed follicular NHL. 40 patients with residual lymphoma after CHOP regimen were treated with rituximab, either in monotherapy or in combination with salvage chemotherapy followed by high dose therapy with stem cell support. We assessed efficacy and tolerance of the treatment.
In 28 patients (70 %) complete remission was achieved and no progression during treatment of rituximab was noticed.